Jessica Chow

Jessica Chow

Auto-generated profile, based on publicly available information

Jessica Chow

Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Journal of Surgical Education
Verified
Journal Article
Closed access
MSMaxwell B. Singer
Maxwell B. Singer
JFJulia J. Fu
Julia J. Fu
JCJessica Chow
Jessica Chow
CTChristopher C. Teng
Christopher C. Teng

1 March 2021 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
BSBenjamin J. Steren
Benjamin J. Steren
BYBenjamin Young
Benjamin Young
JCJessica Chow
Jessica Chow
Importance The coronavirus disease 2019 pandemic illustrates the increasingly important role of telemedicine as a method of clinician-patient interaction. However, electronic applications (apps) for the testing of ophthalmology vital signs, such as visual acuity, can be published and used without any verification of accuracy, validity, or reliability. Objective To reassess the accuracy of visual acuity–testing apps and assess their viability for telehealth. Design, Setting, and Participants The US Apple App Store was queried for apps for visual acuity testing. Anticipated optotype size for various visual acuity lines were calculated and compared against the actual measured optotype size on 4 different Apple hardware devices. No human participants were part of this study. Main Outcomes and Measures Mean (SD) errors were calculated per device and across multiple devices. Results On iPhones, 10 apps met inclusion criteria, with mean errors ranging from 0.2% to 109.9%. On the iPads, 9 apps met inclusion criteria, with mean errors ranging from 0.2% to 398.1%. Six apps met criteria and worked on both iPhone and iPad, with mean errors from 0.2% to 249.5%. Of the 6 apps that worked across devices, the top 3 most accurate apps were Visual Acuity Charts (mean [SD] error, 0.2% [0.0%]), Kay iSight Test Professional (mean [SD] error, 3.5% [0.7%]), and Smart Optometry (mean [SD] error, 15.9% [4.3%]). None of the apps tested were ideal for telemedicine, because some apps displayed accurate optotype size, while others displayed the same letters on separate devices; no apps exhibited both characteristics. Conclusions and Relevance Both Visual Acuity Charts and Kay iSight Test Professional had low mean (SD) errors and functionality across all tested devices, but no apps were suitable for telemedicine. This suggests that new and/or improved visual acuity–testing apps are necessary for optimal telemedicine use.

1 May 2021 in Ophthalmology
Verified
Journal Article
Closed access
PFPaula W. Feng
Paula W. Feng
AAAneesha Ahluwalia
Aneesha Ahluwalia
RARon A. Adelman
Ron A. Adelman
JCJessica H. Chow
Jessica H. Chow

1 January 2009 in Current Eye Research
Verified
Journal Article
Closed access
FDFrancis Char DeCroos
Francis Char DeCroos
SASameer Ahmad
Sameer Ahmad
YKYuji Kondo
Yuji Kondo
JCJessica Chow
Jessica Chow
DMDaniel Mordes
Daniel Mordes
BKBruce Klitzman
Bruce Klitzman
Purpose: Long-term intraocular pressure control by glaucoma drainage implants is compromised by the formation of an avascular fibrous capsule that surrounds the glaucoma implant and increases aqueous outflow resistance. It is possible to alter this fibrotic tissue reaction and produce a more vascularized and potentially more permeable capsule around implanted devices by enclosing them in a porous membrane. Methods: Ahmed glaucoma implants modified with an outer 5-μ m pore size membrane (termed porous retrofitted implant with modified enclosure or PRIME-Ahmed) and unmodified glaucoma implants were implanted into paired rabbit eyes. After 6 weeks, the devices were explanted and subject to histological analysis. Results: A tissue response containing minimal vascularization, negligible immune response, and a thick fibrous capsule surrounded the unmodified Ahmed glaucoma implant. In comparison, the tissue response around the PRIME-Ahmed demonstrated a thinner fibrous capsule (46.4 ± 10.8 μ m for PRIME-Ahmed versus 94.9 ± 21.2 μ m for control, p < 0.001) and was highly vascularized near the tissue-material interface. A prominent chronic inflammatory response was noted as well. Conclusions: Encapsulating the aqueous outflow pathway with a porous membrane produces a more vascular tissue response and thinner fibrous capsule compared with a standard glaucoma implant plate. Enhanced vascularity and a thinner fibrous capsule may reduce aqueous outflow resistance and improve long-term glaucoma implant performance.

1 January 2021 in Journal of Surgical Education
Verified
Journal Article
Closed access
BYBenjamin Young
Benjamin Young
APAndrew Pouw
Andrew Pouw
ARAmanda Redfern
Amanda Redfern
FCFei Cai
Fei Cai
JCJessica Chow
Jessica Chow

2 July 2022 in Ophthalmology
Verified
Journal Article
Closed access
TMTahreem A. Mir
Tahreem A. Mir
SMSumarth Mehta
Sumarth Mehta
KQKaren Qiang
Karen Qiang
RARon A. Adelman
Ron A. Adelman
LPLucian V. Del Priore
Lucian V. Del Priore
JCJessica Chow
Jessica Chow